Keybank National Association OH Has $1.17 Million Position in Quest Diagnostics Incorporated (NYSE:DGX)

Keybank National Association OH raised its position in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 25.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,917 shares of the medical research company's stock after purchasing an additional 1,409 shares during the quarter. Keybank National Association OH's holdings in Quest Diagnostics were worth $1,170,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Bruce G. Allen Investments LLC increased its stake in shares of Quest Diagnostics by 57.8% in the first quarter. Bruce G. Allen Investments LLC now owns 183 shares of the medical research company's stock worth $31,000 after acquiring an additional 67 shares during the last quarter. Golden State Wealth Management LLC increased its stake in shares of Quest Diagnostics by 157.3% in the first quarter. Golden State Wealth Management LLC now owns 193 shares of the medical research company's stock worth $33,000 after acquiring an additional 118 shares during the last quarter. NBC Securities Inc. acquired a new position in shares of Quest Diagnostics in the first quarter worth $35,000. Continuum Advisory LLC increased its stake in shares of Quest Diagnostics by 11,100.0% in the first quarter. Continuum Advisory LLC now owns 224 shares of the medical research company's stock worth $38,000 after acquiring an additional 222 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of Quest Diagnostics in the fourth quarter worth $54,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Quest Diagnostics Price Performance

NYSE:DGX traded down $3.14 during mid-day trading on Monday, hitting $173.78. The company's stock had a trading volume of 839,409 shares, compared to its average volume of 991,041. The stock has a fifty day moving average of $176.47 and a 200-day moving average of $167.99. Quest Diagnostics Incorporated has a fifty-two week low of $136.99 and a fifty-two week high of $182.38. The company has a market capitalization of $19.40 billion, a price-to-earnings ratio of 21.97, a P/E/G ratio of 2.47 and a beta of 0.49. The company has a current ratio of 1.44, a quick ratio of 1.31 and a debt-to-equity ratio of 0.84.

Quest Diagnostics (NYSE:DGX - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The medical research company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.15 by $0.06. The company had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.63 billion. Quest Diagnostics had a net margin of 8.81% and a return on equity of 15.11%. As a group, equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 EPS for the current fiscal year.

Quest Diagnostics Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 21st. Stockholders of record on Monday, July 7th will be issued a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 1.84%. The ex-dividend date is Monday, July 7th. Quest Diagnostics's payout ratio is 40.46%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on DGX. Redburn Atlantic began coverage on shares of Quest Diagnostics in a research note on Wednesday, April 2nd. They issued a "buy" rating and a $195.00 price target on the stock. Redburn Partners set a $195.00 price objective on shares of Quest Diagnostics in a report on Wednesday, April 2nd. Truist Financial upped their price objective on shares of Quest Diagnostics from $182.00 to $190.00 and gave the stock a "hold" rating in a report on Wednesday, April 23rd. Robert W. Baird upped their price objective on shares of Quest Diagnostics from $191.00 to $194.00 and gave the stock an "outperform" rating in a report on Wednesday, April 23rd. Finally, Barclays upped their price objective on shares of Quest Diagnostics from $175.00 to $185.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 23rd. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $185.73.

Insider Buying and Selling at Quest Diagnostics

In related news, SVP Mark E. Delaney sold 874 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $175.72, for a total value of $153,579.28. Following the completion of the sale, the senior vice president owned 8,372 shares of the company's stock, valued at $1,471,127.84. This trade represents a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 8.16% of the company's stock.

Quest Diagnostics Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.